Well said. Clearly the author is ignorant of these basic facts and definitions. Anyone who tries to compare Israel to an apartheid state is either a liar or an imbecile.
I found $DKNG back at $34,March madness is coming traditionally it goes up. There is room for it to go back to where it was. I expect some profit taking to take place soon. So maybe a dip before next up to the $50+.
Looking past the mega-caps are many names that have great potential, including Intra-Cellular Therapies ($ITCI), which has something special with its Caplyta treatment. This drug was on the market for schizophrenia starting in March 2020 and saw solid growth (from zero to 2,000 prescriptions per month) through 2021, but then came a broad approval for bipolar depression, which has bumped the prescription figures to an average of 8,500 during the past two years. It’s the only therapy approved for both bipolar I and II both as a stand-alone and combo offering. Given that there are 11 million bipolar sufferers in the U.S. alone, the potential is huge. Meanwhile, Intra-Cellular is in Phase III trials with Caplyta for major depressive disorder, which is a market potentially twice the size of bipolar. Clinical data released back in March was superb. Sales growth is slowing as the figures get larger, but revenues still rose 76% in Q3, with 2024 expected to bring a 41% gain (likely conservative), with tons of upside if/when MDD approval hits down the road. ITCI has been range bound since April of 2022, but is showing some solid strength since the market low.
Latest Comments
Q2 Earnings Growth Forecasted To Hit Two-Year High
I just bought both!
3 High Growth Tech Stocks For Dividends
Good stock pics. I have all 3.
America Is Not A Black Country, Nor Is It A Jewish Country
Well said. Clearly the author is ignorant of these basic facts and definitions. Anyone who tries to compare Israel to an apartheid state is either a liar or an imbecile.
Chart Of The Day: Should You Bet On DraftKings?
I found $DKNG back at $34,March madness is coming traditionally it goes up. There is room for it to go back to where it was. I expect some profit taking to take place soon. So maybe a dip before next up to the $50+.
Market Signals For The U.S. Stock Market And Indian Stock Market - Monday, Dec. 25
Thanks.
SaverOne: Publicly Traded Tech Startup With Highly Positively Skewed Risk-Reward Ratio
Impressive.
Dow Hits Record Highs After Fed Decision
See... everything is fine.
Macy’s Shares Soar After Reports Of $5.8b Buyout Offer
Are These Biotechs Ready To Launch?
Looking past the mega-caps are many names that have great potential, including Intra-Cellular Therapies ($ITCI), which has something special with its Caplyta treatment. This drug was on the market for schizophrenia starting in March 2020 and saw solid growth (from zero to 2,000 prescriptions per month) through 2021, but then came a broad approval for bipolar depression, which has bumped the prescription figures to an average of 8,500 during the past two years. It’s the only therapy approved for both bipolar I and II both as a stand-alone and combo offering. Given that there are 11 million bipolar sufferers in the U.S. alone, the potential is huge. Meanwhile, Intra-Cellular is in Phase III trials with Caplyta for major depressive disorder, which is a market potentially twice the size of bipolar. Clinical data released back in March was superb. Sales growth is slowing as the figures get larger, but revenues still rose 76% in Q3, with 2024 expected to bring a 41% gain (likely conservative), with tons of upside if/when MDD approval hits down the road. ITCI has been range bound since April of 2022, but is showing some solid strength since the market low.
Lifetime Subscriptions To End Nov. 30th - Last Chance
Thanks for the headsup.